Form 4 for FDMT 4D Molecular Therapeutics, Inc.
Accepted 2024-03-29 00:00:00 ET · period of report 2024-03-27 · accession 0000950170-24-038731 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2024-03-29 | 2024-03-27 | FDMT | Bizily Scott | CLO | S - Sale+OE | $35.04 | -5,833 | 1,737 | -77% | -$204.4K |
| DMT | 2024-03-29 | 2024-03-27 | FDMT | Bizily Scott | CLO | M - OptEx | $25.98 | +5,833 | 7,570 | +336% | +$151.5K |
| DMT | 2024-03-29 | 2024-03-27 | FDMT | Bizily Scott | CLO | M - OptEx | $0.00 | -5,833 | 55.7K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-27 | S | D | 5,833 | $35.04 | 1,737 | D | — | — | (F2) The transaction was executed in multiple trades in prices ranging from $35.00 to $35.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2024-03-27 | M | A | 4,342 | $25.98 | 6,079 | D | — | — | |
| 3 | Common | Common Stock | 2024-03-27 | M | A | 1,491 | $25.98 | 7,570 | D | — | — | |
| 4 | Derivative | Stock Option (Right To Buy) | 2024-03-27 | M | D | 1,491 | $0.00 | 54,167 | D | $25.98 · — to 2031-09-30 | 1,491 Common Stock | (F3) 25% of the shares subject to the option vest on the first anniversary measured from October 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |
| 5 | Derivative | Stock Option (Right To Buy) | 2024-03-27 | M | D | 4,342 | $0.00 | 55,658 | D | $25.98 · — to 2031-09-30 | 4,342 Common Stock | (F3) 25% of the shares subject to the option vest on the first anniversary measured from October 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |